In a filing, Syndax Pharmaceuticals Inc revealed its Chief Financial Officer Goldan Keith A. unloaded Company’s shares for reported $12033.0 on Jul 16 ’25. In the deal valued at $9.29 per share,1,296 shares were sold. As a result of this transaction, Goldan Keith A. now holds 92,450 shares worth roughly $1.16 million.
Then, Metzger Michael A sold 7,534 shares, generating $69,953 in total proceeds. Upon selling the shares at $9.29, the Chief Executive Officer now owns 298,661 shares.
Before that, Goldan Keith A. bought 1,296 shares. Syndax Pharmaceuticals Inc shares valued at $12,034 were divested by the Officer at a price of $9.29 per share.
BTIG Research reiterated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on August 05, 2025; the price target was $56. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. UBS began covering SNDX with “Buy” recommendation on October 24, 2024. Jefferies started covering the stock on June 28, 2024. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 21.10% to $12.57. Over the last five days, the stock has gained 21.45%. Syndax Pharmaceuticals Inc shares have fallen nearly -42.86% since the year began. Nevertheless, the stocks have fallen -4.92% over the past one year.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-07-15, growing by 1.69 million shares to a total of 23.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 22.0 million shares. There was a rise of 7.13%, which implies that there is a positive sentiment for the stock.
